How to Develop a Comprehensive Ventricular Assist Device Program
|
|
|
- Clare Anderson
- 5 years ago
- Views:
Transcription
1 How to Develop a Comprehensive Ventricular Assist Device Program Rodrigo V. González, MD, MS Sección de Cirugía Cardiovascular División de Cirugía Facultad de Medicina Pontificia Universidad Católica de Chile
2 No conflict of interest 2
3 HEART TRANSPLANT IN CHILE N Year REGISTRO NACIONAL DE TRASPLANTES CHILE 2017
4 UNOS STATUS AT THE TIME OF HTx CHILE 2011 and 2017 HTx in Chile 2011 STATUS I 28% HTx in Chile 2017 STATUS II 72% STATUS II 39% STATUS I 61% REGISTRO NACIONAL DE TRASPLANTES CHILE
5 % of Patients Adult Heart Transplants % of Patients Bridged with Mechanical Circulatory Support* by Year and Device Type ECMO TAH VAD+ECMO LVAD+RVAD 40 RVAD LVAD Year of Transplant 2017 JHLT Oct; 36(10): * LVAD, RVAD, TAH, ECMO
6 SHORT TERM VADS 6
7 MANAGEMENT OF ACUTE HEART FAILURE (INTERMACS 1) ECMO ± LV vent (LV apex or RPSV, ASD creation, Impella) MOF Neurologic Injury Acute Heart Failure INTERMACS 1 ROTAFLOW PUMP QUADROX OXIGENATOR HEPARIN COATED LINES Bridge to Decision Bridge to Recovery CENTRIMAG PUMP HEPARIN COATED LINES Short Term VAD (LVAD,RVAD, BIVAD) Bridge to Transplant 7
8 INTERMACS 1: ECMO TO VAD TAKEDA K. ET AL
9 LONG TERM VADS 9
10 Left ventricular assist device (LVAD) program in Chile: first successful experience in South America. Pedemonte O et al. J Thorac Dis 2018;10(Suppl 15):S1751-S1757 Long Term LVAD used: HVAD (HeartWare) Institution: Hospital Gustavo Fricke, Viña del Mar, Chile N : 9 patients (7 males, 2 females); Age : 39 ± 15 (range 15-57) Implantation Period: Diagnosis: Ischemic CM 4, DCM 3, dhocm 1, Chemo Induced CM 1 Indications: Bridge to TX : 8 Destination Therapy : 1 Financing: Kaplan Foundation (private) Preoperative support: ECMO 1 (DCM) IABP 1 (Ischemic CM) INTERMACS n Surgical Technique: Left Anterolateral Thoracotomy + Partial Sternotomy 8 Full sternotomy 1 10
11 Left ventricular assist device (LVAD) program in Chile: first successful experience in South America. Pedemonte O et al. J Thorac Dis 2018;10(Suppl 15):S1751-S1757 Operative mortality: 1/9 (11,1%) MOF (Intermacs 1 patient) ICUS (days): 8,7 ± 5,5 (range 5-23) HLOS (days): 17,2 ± 3,8 (range 12-23) Follow up (8 patiets) 1 patient died 11 months after implantation stroke 1 patient Htx after 16 month 6 patients remain on LVAD mean 846 days (range ) Survival rate: 89%, 78% and 78% at 6, 12 and 18 month 11
12 Left ventricular assist device (LVAD) program in Chile: first successful experience in South America. Pedemonte O et al. J Thorac Dis 2018;10(Suppl 15):S1751-S1757 ADVERSE EVENTS Adverse events <90 days days >180 days Total Reexploration for bleeding (n) Renal dysfunction (n) Hepatic dysfunction (n) Sepsis (n) Driveline infection (n) Cerebrovascular accident (n) Digestive bleeding (n) Arrhythmias (n) LVAD thrombosis (n) Outflow stenosis (n)
13 VAD CASES AT HOSPITAL CLINICO UNIVERSIDAD CATOLICA DE CHILE (PEDIATRICS) Patient Age Date of Pre-VAD VAD Days in Actual n (y) INTERMACS Insertion Support VAD System Type Device State Observation Apr/2009 Berlin Heart BIVAD 14 Dead Pulmonary haemorrhage Dec/2015 ECMO Berlin Heart BIVAD 123 Dead RVAD pump failure, brain damage Mar/2011 Centrimag BIVAD 31 HTX Alive Jan/2014 Centrimag BIVAD 102 HTX Alive Dec/2014 Centrimag BIVAD 103 HTX Alive Aug2015 Heart Ware LVAD 1008 HTX Alive 2 cerebral haemorrhages, required neurosurgical drainage. No sequelae Moya-Moya disease, stroke, driveline infection Jan/2017 Heart Ware LVAD 397 HTX Alive Jun/2018 Heart Mate 3 LVAD 144 LVAD Sep/2018 Centrimag Heart Mate 3 LVAD 27 LVAD Severely malnourished, mechanical ventilation Mean 10 1,89 216,5 13
14 Heart Transplant Centers in Chile Public Health System ADULTS Instituto Nacional del Tórax, Santiago (Metropolitan Region) Hospital Gustavo Fricke, Viña del Mar (North) Hospital Guillermo Grant Benavente, Concepción (South) PEDIATRICS Hospital Clínico Universidad Católica de Chile (whole country)
15 CHILE (4300 km North-South) TOTAL POPULATION (2017) (F 51,1% M 48,9%) HGF PUBLIC HEALTH SYSTEM 75-80% population INT HCUC INT (Santiago) Metropolitan Region years HGF (Viña del Mar) years HGGB HGGB (Concepción) years HCUC (PEDIATRIC Santiago) Population < 20 years (27.2%)
16 Long Term VAD Program in Chile Ministry of Health HGF National Transplant Coordinator INT HGGB FONASA Public Insurance ($) HCUC Long Term VAD Program
17 Long term VAD program in Chile The public insurance (FONASA) will provide the finantial support Includes rd generation pumps per year, with continious flow and magnetic levitation: Heart Ware Heart Mate 3 The devices will be used only as a bridge to transplant, in patients already in the national waiting list for heart transplantation
18 Long term VAD program in Chile Inclusion Criteria: Age 60 years INTERMACS profile 2 or 3 Only UNIVENTRICULAR assistance (LVAD or RVAD) Estimated time in the waiting list for HTx > 45 days (estimated time < 45 days, Centrimag VAD will be considered)
19 Long term VAD program in Chile Patients in INTERMACS 1 connected to ECMO, will be considered if: No CNS damage No evidence of heart recovery Evidence of recovery of all other organs Meets all inclusion criteria
20 Long term VAD Program in Chile Exclusion criteria Biventricular failure High probability of right ventricular Right Ventricular failure Cardiac Failure Review, 2015; 1(1): 25-30
21 Long term VAD program in Chile Relative Exclusion Criteria Previous cardiac surgery Complex congenital heart disease Each case should be discussed individually
22 Long term VAD program in Chile Any potential receptor of a long term VAD: Will be presented and discussed in an expert committee, with at least one representative of each of the other centers and the National Coordinator of the National Transplant Program They will decide if the patient can receive the device for implantation A registry will be kept of the results of the implants and its complications If better VAD systems reach the market in the future, the expert committee will evaluate its incorporation to the program
23 THANK YOU
ECMO as a Bridge to Heart Transplant in the Era of LVAD s.
Christian Bermudez MD. Associate Professor Director Thoracic Transplantation Division Cardiac Surgery Department of Surgery University of Pennsylvania ECMO as a Bridge to Heart Transplant in the Era of
Bridge to Heart Transplantation
Bridge to Heart Transplantation Ulf Kjellman MD, PhD Senior Consultant Surgeon Heart Centre KFSH&RC 1 Disclosure Appointed for Proctorship by Thoratec/St.Jude/Abbott 2 To run a full overall covering transplant
Mechanical assist patient selection, device selection, and outcomes
Mechanical assist patient selection, device selection, and outcomes Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine
Implantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013
Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective
Mechanical Circulatory Support in the Management of Heart Failure
Mechanical Circulatory Support in the Management of Heart Failure Feras Bader, MD, MS, FACC Associate Professor of Medicine Director, Heart Failure and Transplant Cleveland Clinic Abu Dhabi Chairman, Heart
Understanding the Pediatric Ventricular Assist Device
Understanding the Pediatric Ventricular Assist Device W. James Parks, MSc., MD Pediatric Cardiologist Assistant Professor of Pediatrics and Radiology Children s Healthcare of Atlanta Sibley Heart Center
How to mend a broken heart: transplantation or LVAD?
SCDU DI CARDIOCHIRURGIA Università degli Studi di Torino Ospedale S. Giovanni Battista Direttore: Prof. Mauro Rinaldi How to mend a broken heart: transplantation or LVAD? Massimo Boffini Mauro Rinaldi
I have nothing to disclose.
I have nothing to disclose. Right ventricular failure and need for biventricular support Friedrich Wilhelm Mohr, MD, PhD Munich, August 27, 2012 Male; date of birth: 19.07.1984 Out clinic visit 10/ 2004:
Management of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist
Dr Stephen Pettit, Consultant Cardiologist Cardiogenic shock Management of Cardiogenic Shock Outline Definition, INTERMACS classification Medical management of cardiogenic shock PA catheters and haemodynamic
Extra Corporeal Life Support for Acute Heart failure
Extra Corporeal Life Support for Acute Heart failure Benjamin Medalion, MD Director Heart and Lung Transplantation Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Campus, Israel Mechanical
What has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD
What has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD Disclosure: I am Director of the Data Coordinating Center for the INTERMACS project and receive support through
เอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
Derivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: the EUROMACS-RHF Risk Score Osama I.I. Soliman, MD, PhD, FACC,
HeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update
HeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update Mark S. Slaughter, MD University of Louisville, KY, USA HeartWare Users Meeting 29 October 2012 Barcelona, Spain HEARTWARE,
Update on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada
Update on Mechanical Circulatory Support AATS May 5, 2010 Toronto, ON Canada Disclosures NONE Emergency Circulatory Support ECMO Tandem Heart Impella Assessment Cardiac Function Pulmonary function Valvular
ORIGINAL ARTICLE. Alexander M. Bernhardt a, *, Theo M.M.H. De By b, Hermann Reichenspurner a and Tobias Deuse a. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery 48 (2015) 158 162 doi:10.1093/ejcts/ezu406 Advance Access publication 29 October 2014 ORIGINAL ARTICLE Cite this article as: Bernhardt AM, De By TMMH, Reichenspurner
New ventricular assist devices. FW Mohr Clinical seminar: Devices for severe heart failure ESC congress Stockholm 2010
New ventricular assist devices FW Mohr Clinical seminar: Devices for severe heart failure ESC congress Stockholm 2010 The real world of CHF Prevalence 1-3% in europe, in the age of 70-80 years up to 10-20%
Complications in CHD with a little help from our friends
Complications in CHD with a little help from our friends Systemic ventricular failure how can the surgeon help? Assist device or transplantation? Michael Huebler (Zurich, CH) Survivors of CHD Curative
Right Ventricular Failure: Prediction, Prevention and Treatment
Right Ventricular Failure: Prediction, Prevention and Treatment 3 rd European Training Symposium for Heart Failure Cardiologists and Cardiac Surgeons University Hospital Bern June 24-25, 2016 Disclosures:
Do we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine
Do we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict
Pediatric Mechanical Circulatory Support - What to Use
Pediatric Mechanical Circulatory Support - What to Use Ronald K. Woods, MD, PhD Associate Professor Medical College of Wisconsin Pediatric Cardiothoracic Surgery Children s Hospital of Wisconsin Disclosure
Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients
http://www.jhltonline.org SPECIAL FEATURE Fifth INTERMACS annual report: Risk factor analysis from more than 6, mechanical circulatory support patients James K. Kirklin, MD, a David C. Naftel, PhD, a Robert
Giving your heart strength. Ventricular Assist Device.
Giving your heart strength. Ventricular Assist Device. 1 National leader in Ventricular Assist Devices Although you may be nervous when considering heart surgery, you can rest assured knowing that UR Medicine
Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis
Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis April 11, 2014 Jason O. Robertson, M.D., M.S.; David C. Naftel, Ph.D., Sunil
Predicting Major Outcomes after MCSD Implant. Risk Factors for Death, Transplant, and Recovery. James Kirklin, MD David Naftel, PhD
Predicting Major Outcomes after MCSD Implant Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD 1 I have no financial disclosures (I am the Principle Investigator for
Status of Implantable VADs
Status of Implantable VADs John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict of Interest Statement
To ECMO Or Not To ECMO Challenges of venous arterial ECMO. Dr Emily Granger St Vincent s Hospital Darlinghurst NSW
To ECMO Or Not To ECMO Challenges of venous arterial ECMO Dr Emily Granger St Vincent s Hospital Darlinghurst NSW The Start: 1972 St Vincent s Hospital The Turning Point ECMO program restarted in 2004
ECMO and VAD implantation
1 Udine ECMO Workshop ECMO and VAD implantation Prof. Tomaso Bottio Division of Cardiac Surgery (Director Prof. Gino gerosa) ECMO Extracorporeal membrane oxygena1on (ECMO) is a rescue therapy to support
Ventricular Assist Devices for Permanent Therapy: Current Status and Future
Ventricular Assist Devices for Permanent Therapy: Current Status and Future Prospects Francis D. Pagani MD PhD Professor of Cardiac Surgery University of Michigan April 28 th, 2012 Disclosures NHLBI and
None. Declaration of conflict of interest
None Declaration of conflict of interest New Long Term Circulatory Support Technology and Treatment Strategies Stephen Westaby Oxford, UK Cardiac Transplantation: Facts from the UNOS Database Median survival
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know! Matthew A. Wanat, PharmD, BCPS, BCCCP, FCCM Clinical Assistant Professor University of Houston College of Pharmacy Clinical Pharmacy
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD
A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD SK Singh MD MSc, DK Pujara MBBS, J Anand MD, WE Cohn MD, OH Frazier MD, HR Mallidi MD Division of Transplant & Assist
Artificial Heart Program
Artificial Heart Program Provider Review: General VAD Overview Indications for VAD Bridge to transplant (BTT) historically most common (~80%) allow rehab from severe CHF while awaiting donor Bridge to
Translating Device and Mechanical Support Guidelines to ACHD Research. Timothy M. Maul, CCP, PhD Perfusionist Sr. Research Scientist
Translating Device and Mechanical Support Guidelines to ACHD Research Timothy M. Maul, CCP, PhD Perfusionist Sr. Research Scientist Disclosures No financial disclosures May discuss off-label or investigational
Seventh INTERMACS annual report: 15,000 patients and counting
http://www.jhltonline.org INTERMACS ANNUAL REPORT Seventh INTERMACS annual report: 15,000 patients and counting James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
Left Ventricular Assist Devices (LVADs): Overview and Future Directions
Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,
Heart Transplant: State of the Art. Dr Nick Banner
Heart Transplant: State of the Art Dr Nick Banner Heart Transplantation What is achieved Current challenges Donor scarcity More complex recipients Long-term limitations Non-specific Pharmacological Immunosuppression
Regional Differences in Utilization and Outcomes of Left Ventricular Assist Devices: Insights from the INTERMACS Registry
Regional Differences in Utilization and Outcomes of Left Ventricular Assist Devices: Insights from the INTERMACS Registry Selim Krim, MD 1 ; Rey Vivo, MD 2 ; Patrick Campbell, MD 1 ; Jerry Estep, MD 3
Lessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward?
Lessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward? Mark S. Slaughter, MD Professor and Chair Department of Cardiovascular and Thoracic Surgery University of Louisville What could
Novel Devices for End-Stage Heart Failure
Novel Devices for End-Stage Heart Failure Lynne Warner Stevenson No conflicts of interest Off-label assist devices and expanded indications will be discussed Devices for End-Stage Heart Failure New definitions
Innovative ECMO Configurations in Adults
Innovative ECMO Configurations in Adults Practice at a Single Center with Platinum Level ELSO Award for Excellence in Life Support Monika Tukacs, BSN, RN, CCRN Columbia University Irving Medical Center,
How do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS
How do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS Rey P. Vivo, MD 1 ; Selim R. Krim, MD 2 ; Jerry D. Estep, MD 3 ; Wissam
HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM
HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM A New Milestone in LVAD Therapy HeartMate 3 Left Ventricular Assist Device Introducing the new HEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY HeartMate 3 LVAD
Outpatient Treatment of MCS Patient. F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA
Outpatient Treatment of MCS Patient F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA Disclosure Statement I DO NOT HAVE ANY RELEVANT FINANCIAL RELATIONSHIPS WITH ANY COMMERCIAL
Minimally Invasive Insertion of HVAD
Minimally Invasive Insertion of HVAD Simon Maltais, MD PhD Vice-Chair of Clinical Practice Director of MCS Program Department of Cardiovascular Surgery Mayo Clinic, Rochester, MN AATS MCS 2018, Houston
Right Heart Failure in LVAD patients: Prevention and Management.
Christian Bermudez MD. Associate Professor Director Thoracic Transplantation Division Cardiac Surgery Department of Surgery University of Pennsylvania Right Heart Failure in LVAD patients: Prevention and
Surgical Options for Advanced Heart Failure
Surgical Options for Advanced Heart Failure Benjamin Medalion, MD Director, Transplantation and Heart Failure Surgery Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Hospital Heart
Challenges to MCS Use in the Middle East
Challenges to MCS Use in the Middle East Feras Khaliel, MD, Ph.D Consultant Cardiac Surgeon Associate Professor of Surgery, Alfaisal Univerisity King Faisal Specialist Hospital & Research Center Dr. Michael
Acute heart failure: ECMO Cardiology & Vascular Medicine 2012
Acute heart failure: ECMO Cardiology & Vascular Medicine 2012 Lucia Jewbali cardiologist-intensivist 14 beds/8 ICU beds Acute coronary syndromes Heart failure/ Cardiogenic shock Post cardiotomy Heart
Implantable Ventricular Assist Devices and Total Artificial Hearts
Implantable Ventricular Assist Devices and Total Artificial Hearts Policy Number: Original Effective Date: MM.06.017 05/21/1999 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical Circulatory Support Relevant Financial Relationship
Size Limitation for Current Continuous Flow Pumps: How young can we go?
Size Limitation for Current Continuous Flow Pumps: How young can we go? Iki Adachi, M.D. Associate Surgeon Texas Children s Hospital Assistant Professor Baylor College of Medicine How young can we go?
Left Ventricular Assist Devices LVAD. North Country EMS Program Agency 3/21/12
Left Ventricular Assist Devices LVAD North Country EMS Program Agency 3/21/12 Objectives Describe indications for and functions of ventricular assist devices (LVAD) Differentiate assessment findings of
VAD come Destination therapy nell adulto con Scompenso Cardiaco
VAD come Destination therapy nell adulto con Scompenso Cardiaco Francesco Santini Division of Cardiac Surgery, IRCCS San Martino IST University of Genova Medical School, Italy Heart Transplantation is
Implantable Ventricular Assist Devices and Total Artificial Hearts
Implantable Ventricular Assist Devices and Total Artificial Hearts Policy Number: Original Effective Date: MM.06.017 05/21/1999 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
Mechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
ORIGINAL ARTICLE. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery 52 (2017) 1055 1061 doi:10.1093/ejcts/ezx189 Advance Access publication 22 June 2017 ORIGINAL ARTICLE Cite this article as: Takeda K, Garan AR, Ando M, Han J,
Heart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
Destination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT.
DT Destination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT. ONLY WE HAVE THIS BREADTH OF CLINICAL EVIDENCE TO SUPPORT DESTINATION THERAPY.
MEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES
MEDICAL POLICY PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
Total Artificial Hearts and Implantable Ventricular Assist Devices
Total Artificial Hearts and Implantable Ventricular Assist Devices Policy Number: 7.03.11 Last Review: 12/2018 Origination: 12/2001 Next Review: 12/2019 Policy Blue Cross and Blue Shield of Kansas City
Strengthening Your VAD Program
Disclosure: I have no financial conflicts of interest. Strengthening Your VAD Program Octavio E. Pajaro MD, PhD Chair, Cardiothoracic Surgery Mayo Clinic Arizona Surgical Director, Heart Transplantation
Surgical Options for Temporary MCS
Surgical Options for Temporary MCS Michael A. Acker, MD Julian Johnson Professor of Surgery Chief of Cardiovascular Surgery Director of Heart and Vascular Center University of Pennsylvania Health System
Ventricular Assist Device. Lauren Bartlett 10/5/16 BME 281, section 1
Ventricular Assist Device Lauren Bartlett 10/5/16 BME 281, section 1 What is a Ventricular Assist Device (VAD)? Electromechanical device for assisting cardiac circulation Used to partially or completely
STATE OF OKLAHOMA 2014 EMERGENCY MEDICAL SERVICES PROTOCOLS
5M VENTRICULAR ASSIST DEVICE (VAD) MANAGEMENT ADULT EMERGENCY MEDICAL DISPATCHER EMERGENCY MEDICAL RESPONDER EMT EMT-INTERMEDIATE 85 ADVANCED EMT PARAMEDIC A Ventricular Assist Device, or VAD, is a mechanical
ECMO as a bridge to durable LVAD therapy. Jonathan Haft, MD Department of Cardiac Surgery University of Michigan
ECMO as a bridge to durable LVAD therapy Jonathan Haft, MD Department of Cardiac Surgery University of Michigan Systolic Heart Failure Prevalence 4.8 million U.S. 287,000 deaths per year $39 billion spent
DECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
Jennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio
Biventricular Heart Failure Advanced Treatment Options at The Cleveland Clinic Jennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio I have no disclosures. Examine respiratory and
Implantable Ventricular Assist Devices and Total Artificial Hearts
Implantable Ventricular Assist Devices and Total Artificial Hearts Policy Number: Original Effective Date: MM.06.017 05/21/1999 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
CABG for ischemic cardiomyopathy, post myocardial infarction and cardiogenic shock
CABG for ischemic cardiomyopathy, post myocardial infarction and cardiogenic shock Yoshiya Toyoda, MD, PhD William Maul Measey Professor of Surgery Chief, Cardiovascular Surgery Surgical Director, Mechanical
Echo assessment of patients with an ECMO device
Echo assessment of patients with an ECMO device Evangelos Leontiadis Cardiologist 1st Cardiology Dept. Onassis Cardiac Surgery Center Athens, Greece Gibbon HLM 1953 Goldstein DJ et al, NEJM 1998; 339:1522
Andrew Civitello MD, FACC
Timing the Transition from Short Term to Long Term Mechanical Circulatory Support Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's
Total Artificial Hearts and Implantable Ventricular Assist Devices
Total Artificial Hearts and Implantable Ventricular Assist Devices Policy Number: 7.03.11 Last Review: 12/2017 Origination: 12/2001 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City
Medical Policy. MP Total Artificial Hearts and Implantable Ventricular Assist Devices
Medical Policy MP 7.03.11 BCBSA Ref. Policy: 7.03.11 Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery Related Policies 7.03.08 Heart/Lung Transplant 7.03.09 Heart Transplant 8.01.60
ECMO AND SHORT-TERM SUPPORT:
ECMO AND SHORT-TERM SUPPORT: UTILIZATION GUIDELINES AND IMPACT OF THE NEW HEART ALLOCATION SYSTEM Jeffrey Teuteberg Section Chief of Heart Failure, Cardiac Transplant and Mechanical Circulatory Support
Berlin Heart Pediatric Assistance Device: The Beginnings, The Teachings And The Cruising Speed : A Monocentric Experience With The Same System
Berlin Heart Pediatric Assistance Device: The Beginnings, The Teachings And The Cruising Speed : A Monocentric Experience With The Same System Roland Henaine, Mathieu Vergnat, Geoffray Keller, Magali Veyrier,
SCOMPENSO CARDIACO AVANZATO Controversia: che fine sta facendo il trapianto cardiaco, è sempre la prima opzione?
University of Pavia School of Medicine San Matteo Hospital, Division of Cardiac Surgery Pavia, Italy Prof. Andrea M. D Armini, M.D. SCOMPENSO CARDIACO AVANZATO Controversia: che fine sta facendo il trapianto
Acute Mechanical Circulatory Support Right Ventricular Support Devices
Acute Mechanical Circulatory Support Right Ventricular Support Devices Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure
Planned, Short-Term RVAD During Durable LVAD Implant: Indications and Management
Planned, Short-Term RVAD During Durable LVAD Implant: Indications and Management Yoshifumi Naka, MD, PhD Columbia University Medical Center New York, NY Disclosure Abbott/St. Jude Med./Thoratec Consultant
Description. Section: Surgery Effective Date: April 15, Subsection: Transplant Original Policy Date: September 13, 2012 Subject:
Last Review Status/Date: March 2016 Page: 1 of 30 Description Mechanical devices to assist or replace a failing heart have been developed over many decades of research. A ventricular assist device (VAD)
Total Artificial Hearts and Implantable Ventricular Assist Devices
Total Artificial Hearts and Implantable Ventricular Assist Devices Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively
First Experiences With the HeartWare Ventricular Assist System in Children
First Experiences With the HeartWare Ventricular Assist System in Children Oliver Miera, MD, Evgenij V. Potapov, MD, PhD, Matthias Redlin, MD, Alexander Stepanenko, MD, Felix Berger, MD, PhD, Roland Hetzer,
HEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU
HEARTMATE 3 WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU HEARTMATE 3 with Full MagLev Flow Technology HEARTMATE 3 DELIVERS UNPRECEDENTED * SURVIVAL AND SAFETY OUTCOMES **1 LANDMARK SURVIVAL
3/1/2017. Chronic Mechanical Support for Heart Failure. Heart Failure is a major driver of morbidity and mortality in the US 1-7
Chronic Mechanical Support for Heart Failure Margarita Camacho MD, FACS Surgical Director Cardiac Transplant and Mechanical Assist Device Program RWJ/Barnabas Health Heart Centers at Newark Beth Israel
THE USE of VENTRICULAR ASSIST DEVICES in CHILDREN: CURRENT OPTIONS & FUTURE TRENDS
THE USE of VENTRICULAR ASSIST DEVICES in CHILDREN: CURRENT OPTIONS & FUTURE TRENDS ADULTS : VAD Better Accepted Technically easier Fewer anatomical constraints HTx is realistic possibility Overall experience
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Total Artificial Hearts and Ventricular Assist Devices Page 1 of 39 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Total Artificial Hearts and Ventricular Assist
Facts. STRONG Risk Factors for HF* LVAD, BiVAD, RVAD, HVAD 10/21/ million adults in the US have heart failure.
10/21/18 1 Facts 5.8 million adults in the US have heart failure. About ½ of those who have HF have a 5 year life expectancy. STRONG Risk Factors for HF* Coronary Heart Disease/MI/Afib COPD Renal Failure
CENTRAL ECMO WHEN AND HOW? RANJIT JOHN, MD UNIVERSITY OF MINESOTA
CENTRAL ECMO WHEN AND HOW? RANJIT JOHN, MD UNIVERSITY OF MINESOTA Background How to do Case reports When to do Managing complications Post operative management strategies CASE PRESENTATION 46 year old
Short and long term mechanical circulatory support: Management in intensive care. Dr Ana Hurtado Consultant Intensivist Harefield Hospital, UK
Short and long term mechanical circulatory support: Management in intensive care Dr Ana Hurtado Consultant Intensivist Harefield Hospital, UK Right device for the right patient why are you doing this?
Modern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies
Modern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies ERIC T. ROME D.O. HEART FAILURE, MECHANICAL ASSISTANCE AND TRANSPLANTATION CVI Left Ventricular Assist Device An
Case - Advanced HF and Shock (INTERMACS 1)
Case - Advanced HF and Shock (INTERMACS 1) Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive Director,
MEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
Name of Policy: Ventricular Assist Devices and Total Artificial Hearts
Name of Policy: Ventricular Assist Devices and Total Artificial Hearts Policy #: 033 Latest Review Date: February 2014 Category: Surgery Policy Grade: A Background/Definitions: As a general rule, benefits
Ventricular Assist Devices and Total Artificial Hearts
Medical Policy Manual Surgery, Policy No. 52 Ventricular Assist Devices and Total Artificial Hearts Next Review: December 2018 Last Review: January 2018 Effective: February 1, 2018 IMPORTANT REMINDER Medical
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Total Artificial Hearts and Ventricular Assist Devices Page 1 of 37 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Total Artificial Hearts and Ventricular Assist
LVADs as a long term or destination therapy for the advanced heart failure
LVADs as a long term or destination therapy for the advanced heart failure Prof. Davor Miličić, MD, PhD University of Zagreb School of Medicine Department of Cardiovascular Diseases University Hospital
Sixth INTERMACS annual report: A 10,000-patient database
http://www.jhltonline.org INTERMACS ANNUAL FEATURE Sixth INTERMACS annu report: A 10,000-patient database James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
The Heart Center Heart Failure and Transplant Program
The Heart Center Heart Failure and Transplant Program Turning heart failure into heart function When your child is experiencing heart problems and regular treatments aren t working, it can be extremely
Why Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support
Why Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support Utpal S Bhalala, MD, FAAP Assistant Professor and Director of Research Pediatric Critical Care